Compare NBBK & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBBK | PHAR |
|---|---|---|
| Founded | 1892 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 926.5M | 793.4M |
| IPO Year | 2023 | 2020 |
| Metric | NBBK | PHAR |
|---|---|---|
| Price | $22.56 | $10.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $23.50 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 239.2K | 17.0K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | ★ 25.23 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $45.15 | $10.04 |
| Revenue Next Year | $4.18 | $2.51 |
| P/E Ratio | ★ $25.18 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.84 | $9.62 |
| 52 Week High | $23.47 | $21.34 |
| Indicator | NBBK | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 48.16 | 41.69 |
| Support Level | $22.28 | $9.62 |
| Resistance Level | $22.71 | $13.51 |
| Average True Range (ATR) | 0.43 | 0.37 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 40.94 | 24.76 |
NB Bancorp Inc operates as the holding company of Needham Bank. The group's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.